Furthermore, Wu et al. identified that overexpression of miR-620 facilitates tumour resistance to gemcitabine-based chemotherapies in TNBC through downregulating dCMP deaminase (DCTD) expression [105]. This evidence concerns the gene DCTD and neoplasm.